Adult Dosing
Infections of the external auditory canal
- Instill 4 gtt into the affected ear(s) tid-qid
- Alt: Place a cotton wick saturated with the solution in the canal for 24 hrs. Moisten the wick q4 hrs with the otic solution
- Max: 10 consecutive days
Infections of mastoidectomy & fenestration activities (otic suspension only)
- Instill 4 gtt into the affected ear(s) tid-qid
- Alt: Place a cotton wick saturated with the suspension in the canal for 24 hrs. Moisten the wick q4 hrs with the otic suspension
- Max: 10 consecutive days
Note:
- External auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator
- Patient should lie with the affected ear upward and the drops should be instilled; this position should be maintained for 5 mins
Pediatric Dosing
Infections of the external auditory canal
Children >2 yrs
- Instill 3 gtt into the affected ear(s) tid-qid
- Max: 10 consecutive days
Infections, mastoidectomy and fenestration cavities (otic suspension only)
- Instill 3 gtt into the affected ear(s) tid-qid
- Max: 10 consecutive days
Note:
- External auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator
- Patient should lie with the affected ear upward and the drops should be instilled; this position should be maintained for 5 mins
[Outline]
See Supplemental Patient Information
- For use in ears only; should not be used in the eyes
- Neomycin component of the combination drug may induce permanent sensorineural hearing loss due to cochlear damage. Prolonged use may increase the risk of ototoxicity; therefore, duration of therapy should be limited to 10 consecutive days
- Closely monitor the patient being treated with eardrops containing neomycin. Therapy is contraindicated in patients with a perforated tympanic membrane
- Neomycin may cause cutaneous sensitization; promptly discontinue therapy if sensitization or irritation occurs
- While treating secondary infections such as chronic otitis externa or stasis dermatitis using neomycin-containing products, it should be noted that skin in these conditions is more liable than the normal skin to become sensitized to many substances, including neomycin
- Sensitization to neomycin may present as low-grade reddening with swelling, dry scaling, and itching. Evaluate regularly for such signs, and advise patients to discontinue the product if such signs occur and also to avoid future use of neomycin-containing products
- Product (solution form) contains potassium metabisulfite, which may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. Sulfite sensitivity is more frequent in asthmatic people
- Prolonged use of therapy may result in overgrowth of nonsusceptible organisms, including fungi. If the infection is not recovered after 1 week, cultures and susceptibility tests should be repeated to verify the organism and to determine whether therapy should be changed
- Allergic cross-reactions may occur, which could prevent future use of any or all of the following aminoglycoside antibiotics such as kanamycin, paromomycin, streptomycin, and possibly gentamycin
Cautions: Use cautiously in
- Prolonged use
- Pregnancy
- Lactation
Supplemental Patient Information
- Advise patients to avoid contaminating the dropper with material from the ear, fingers, or other source in order to preserve the sterility of the drops
- Instruct patients to stop use and consult their physician if sensitization or irritation occurs
Pregnancy Category:C
Breastfeeding: Safety unknown. Hydrocortisone: Systemically absorbed corticosteroids may have minimal excretion in breast milk. Neomycin could result in very low levels in breastmilk and present negligible risk to the nursing infants. Polymyxin B is minimally absorbed after topical application; hence, it poses a low risk to the nursing infant. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 24 June 2011). As per manufacturer's data, since systemic absorption of hydrocortisone may occur when applied topically; caution should be exercised while using in nursing women.
US Trade Name(s)
- Cortisporin
- Oticair
- Pediotic
US Availability
hydrocortisone/neomycin/polymyxin B (generic)
- SOLN: [1%/3.5 mg/10,000 units]/mL
- SUSP: [1%/3.5 mg/10,000 units]/mL
Cortisporin (hydrocortisone/neomycin/polymyxin B)
- SOLN: [1%/3.5 mg/10,000 units]/mL
- SUSP: [1%/3.5 mg/10,000 units]/mL
Oticair (hydrocortisone/neomycin/polymyxin B)
- SUSP: [1%/3.5 mg/10,000 units]/mL
Pediotic (hydrocortisone/neomycin/polymyxin B)
- SUSP: [1%/3.5 mg/10,000 units]/mL
Canadian Trade Name(s)
- Cortisporin
- Cortimyxin
- Spor-HC
Canadian Availability
Cortisporin (hydrocortisone/neomycin/polymyxin B)
- SOLN: [1%/3.5 mg/10,000 units]/mL
Cortimyxin (hydrocortisone/neomycin/polymyxin B)
- SOLN: [1%/3.5 mg/10,000 units]/mL
Spor-HC (hydrocortisone/neomycin/polymyxin B)
- SUSP: [1%/3.5 mg/10,000 units]/mL
UK Trade Name(s)
UK Availability
Otosporin (hydrocortisone/neomycin/polymyxin B)
- SOLN: [1%/3.5 mg/10,000 units]/mL
Australian Trade Name(s)
Australian Availability
[Outline]
Pricing data from www.DrugStore.com in U.S.A.
- Pediotic 3.5-10000-1 SUSP [Bottle] (MONARCH PHARMACEUTICALS)
7.5 = $59.99
22.5 = $179.97 - Cortisporin 3.5-10000-1 SOLN [Bottle] (MONARCH PHARMACEUTICALS)
10 = $84.99
30 = $236.98
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.